IL-15 is a potential target for such treatment, as it is highly expressed in lesions of human cutaneous leishmaniasis patients and promotes the expression of granzyme B dependent CD8 T cell cytotoxicity. The gene discussed is CD8A; the disease is cutaneous leishmaniasis.